Hyundai ADM Bio Declares Strategic Pivot to Lead Post-Patent Immunotherapy Combination Era

As the patent landscape shifts in the global oncology market, Hyundai ADM Bio (KOSDAQ symbol 187660) is rebalancing its focus towards immunotherapy-based combinations, abandoning its IND application for Phase 1 clinical trials involving Penetrium(TM) and docetaxel. This strategic redirection reflects a broader shift in the industry, driven by the impending expiration of key patents in 2028 and the growing importance of immune checkpoint inhibitors, exemplified by Merck's Keytruda, which has been investigated in over 1,600 combination trials worldwide.

Key Takeaways:

• Hyundai ADM Bio has voluntarily withdrawn its IND application for Phase 1 clinical trials evaluating Penetrium(TM) in combination with docetaxel, opting to resubmit an IND application within this month for a new trial combining Penetrium(TM) with immune checkpoint inhibitors.
• The company's decision reflects a strategic pivot aligned with the structural transformation of the global oncology landscape and a refined understanding of tumor microenvironment dynamics, with a focus on ECM reprogramming to overcome the ECM barrier in tumors.
• Penetrium(TM), an ECM-modifying therapeutic, has demonstrated in preclinical data efficacy when paired with anti-PD-1 therapy in triple-negative breast cancer in vivo models, reducing tumor volume by 48.3% compared to monotherapy.
• Industry observers have described Penetrium(TM) as the most clinically advanced ECM-based immunotherapy combination candidate to date, with potential to serve as a backbone in post-patent immuno-oncology strategies.
• Hyundai ADM Bio plans to initiate new combination trials, starting with triple-negative breast cancer and metastatic lung cancer, followed by expansion into broader solid tumor indications.
• The move is viewed as a pioneering step towards establishing scientific and strategic leadership in the post-patent era of immune oncology combinations.

Statistics:

• The global immuno-oncology market is expected to expand from $43.7 billion in 2023 to $284.7 billion by 2033.
• Penetrium(TM) has been demonstrated in preclinical data to reduce tumor volume by 48.3% when paired with anti-PD-1 therapy in triple-negative breast cancer in vivo models.
• Merck's immune checkpoint inhibitor Keytruda has been investigated in over 1,600 combination trials worldwide.
• Hyundai ADM Bio plans to expand its development strategy to secure global leadership in combination immunotherapy.

Sources:

• "Hyundai ADM Bio Declares Strategic Pivot to Lead Post-Patent Immunotherapy Combination Era", PRNewswire, May 13, 2025.
• "Penetrium(TM) Demonstrates Efficacy in Preclinical Data", AACR Annual Meeting 2025.
• "Global Immuno-Oncology Market Expected to Reach $284.7 Billion by 2033", Industry Analysts.